There are currently 1095 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Loncastuximab Tesirine in WM
NCT05190705
Recruiting
This study is being done to examine the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The name of the study drug involved in this study is: * Loncastuximab tesirine
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Waldenstrom Macroglobulinemia
Register for Updates
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
NCT05850234
Recruiting
This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Research Site, Rochester, Minnesota
Conditions: Relapsed/ Refractory Multiple Myeloma
Register for Updates
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
NCT06042725
Recruiting
This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with lenalidomide and dexamethasone, daratumumab and dexamethasone, or daratumumab, lenalidomide, and dexamethasone in treating patients with multiple myeloma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Lenalidomide is a drug that is similar to thalidomide, and i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Multiple Myeloma
Register for Updates
Identification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters
NCT06207188
Recruiting
This study is being done to identify and differentiate thyroid nodules by acoustic imaging and viscoelastic parameters.
Gender:
ALL
Ages:
8 years and above
Trial Updated:
05/20/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Thyroid Gland Carcinoma
Register for Updates
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
NCT06328777
Recruiting
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/20/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Systemic Sclerosis, Scleroderma
Register for Updates
Patient and Caregiver Priorities in Neuro-oncology Care
NCT06676306
Recruiting
This study is being done to identify patient and caregiver burdens regarding their experience with diagnosis and treatment of CNS tumors. These results will help doctors find areas where patients and caregivers may need more support.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Malignant Central Nervous System Neoplasm, Metastatic Malignant Neoplasm in the Central Nervous System
Register for Updates
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
NCT06839235
Recruiting
The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult participants will be treated with a single ascending dose to identify a recommended dose. In Part B, pediatric participants will be treated with the recommended dose. Following the first Study Period, parti... Read More
Gender:
ALL
Ages:
Between 6 years and 64 years
Trial Updated:
05/20/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Primary Hyperoxaluria Type 1 (PH1)
Register for Updates
Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy
NCT06953245
Recruiting
This study evaluates patient-reported experiences of radiation dermatitis in patients with breast cancer undergoing radiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Breast Carcinoma
Register for Updates
The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction
NCT05109208
Recruiting
Researchers are trying to determine whether there is additional utility to using vibroelastography, a noninvasive ultrasound technique to evaluate for the presence of tissue fibrosis, in conjunction with standard penile duplex Doppler ultrasound to assess erectile function (recovery) after prostate cancer surgery.
Gender:
MALE
Ages:
40 years and above
Trial Updated:
05/19/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Prostate Adenocarcinoma
Register for Updates
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222
Recruiting
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Register for Updates
RECOVER-ENERGIZE Platform Protocol
NCT06404047
Recruiting
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Long COVID, Long Covid19, Long Covid-19
Register for Updates
Avalus Ultra Post-Approval Study (PAS)
NCT06506903
Recruiting
The purpose of this study is to characterize the safety and effectiveness of the Medtronic Avalus Ultra aortic valve bioprosthesis in patients with aortic valve disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Aortic Valve Disease
Register for Updates